Cardax

Cardax Short-term Debt

The Short-Term Debt of Cardax (CDXI) as of Oct 19, 2026 is 2.80 M USD. In the previous year, Short-Term Debt was 358,300.00 USD — a change of 682.25% (higher).

Short-term Debt

2.80 MUSD

YoY

682.25%

Last updated:

Short-Term Debt of Cardax is 2020 2.80 M USD. Short-Term Debt of Cardax was 2019 358,300.00 USD. It decreases by 682.25% higher compared to the previous year.

The Cardax Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
358,300.00 USD
Jan 1, 2020
2.80 M USD
The Cardax Short-term Debt history
YEARShort-term DebtYoY
2.80 MUSD+682.25%
358,300.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

Short-Term Debt of Cardax is 2.80 M USD in 2020.

Short-Term Debt of Cardax changed from 358,300.00 USD to 2.80 M USD, representing a 682.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Cardax since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Cardax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cardax

All Key Metrics — Cardax